F32 F33 F41.2
Conditions
Interventions
Group 1: Retrospective analysis of all patients with two dispensation of the same antidepressant (AD) between Q3 2018 and Q4 2019 and with at least one dispensation of an augmentation drug after the s
Sponsors
Medizinische Hochschule Brandenburg - Theodor Fontane
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Patients with one of the following ICD 10 diagnoses between Q3 2018 and Q4 2019: F32, F33, F41.2 2. Patients with at least two dispensation for the same antidepressant between Q3 2018 and Q4 2019 on different days 3. Patients with dispensing of a medication for augmentation in 2019 4. Place of residence in Germany 5. The minimum age of 18 years had to be reached in the observation period (Q1-Q4 2019) 6. At least one day of insurance in 2019 and continuous insurance time of at least two years before 2019 as pre-observation period
Exclusion criteria
Exclusion criteria: 1. Patients with missing information on gender, the gender information diverse or with the gender specified as unknown. 2. Patients with missing or implausible information on age. 3. Comorbid diagnosis of schizophrenia, schizoaffective disorder, bipolar disorders, or dementia were excluded, unless this condition was suffered only under MDE therapy (schizophrenia, dementia) or the indication switched after initially being diagnosed with a unipolar depression during the Q3-Q4 2018 (bipolar disorders).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients with at least two dispensations of the same antidepressant (AD) between Q3 2018 and Q4 2019 and with at least one dispensation of an augmentation agent after the second dispensing of the primary AD between Q1 and Q4 2019 for one of the following four strategies: i) lithium (independent of any further prescribed substances), ii) one or more second-generation antipsychotics (independent of any further prescribed substances, expect lithium), iii) one or more additional AD, and iv) any other relevant psychopharmaceutical while maintaining the primary AD. The analysis uses health insurance claims data which originates from the German Pharmacoepidemiological Research Database (GePaRD) of the Leibniz-Institut für Präventionsforschung und Epidemiologie – BIPS. | — |
Countries
Germany
Outcome results
None listed